Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Diagnostic procedures that find residual disease may help predict if the disease will come back in patients diagnosed with acute myeloid leukemia.
PURPOSE: This research trial studies the comparison of laboratory test results for minimal residual disease in samples from patients with acute myeloid leukemia.
|Leukemia||Other: diagnostic laboratory biomarker analysis Other: flow cytometry|
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia|
- Degree of concordance in the MRD assay results between laboratories
Biospecimen Retention: Samples With DNA
|Study Start Date:||February 2012|
|Primary Completion Date:||July 2016 (Final data collection date for primary outcome measure)|
- To promote harmonization between Cooperative Group Reference Laboratories conducting minimal-residual disease (MRD) evaluation of acute myeloid leukemia by flow cytometry.
OUTLINE: Archived bone marrow and blood samples, distributed to the Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B laboratories, are analyzed for leukemia-associated immunophenotype (LAIP) assays and minimal residual disease studies by flow cytometry. Results are then provided to the National Cancer Institute for assessment and comparability of test results.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01498302
|Principal Investigator:||J. Milburn Jessup, MD||National Cancer Institute (NCI)|